Aspirin Resistance and Ischemic Stroke

1 Manojna Konda, MD University of Arkansas. GBD Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2021;20:795–820. doi:10.1016/S1474-4422(21)00252-0. Search in Google Scholar

2 Schlemm L. Disability Adjusted Life Years due to Ischaemic Stroke Preventable by Real-Time Stroke Detection-A Cost-Utility Analysis of Hypothetical Stroke Detection Devices. Front Neurol. 2018;9:814. doi: 10.3389/fneur.2018.00814. Search in Google Scholar

3 Yatsu FM, Yamaguchi T, Norrving B. International aspects of global stroke burden. Int J Stroke. 2006;1(4):222-3. doi: 10.1111/j.1747-4949.2006.00067.x. Search in Google Scholar

4 Bonita R, Mendis S, Truelsen T, Bogousslavsky J, Toole J, Yatsu F. The global stroke initiative. Lancet Neurol. 2004;3(7):391-3. doi: 10.1016/ S1474-4422(04)00800-2. Search in Google Scholar

5 Rothlisberger JM, Ovbiagele B. Antiplatelet therapies for secondary stroke prevention: an update on clinical and cost-effectiveness. J Comp Eff Res. 2015;4(4):377-84. doi: 10.2217/cer.15.22. Search in Google Scholar

6 Roth GJ, Calverley DC. Aspirin, platelets, and thrombosis: theory and practice. Blood. 1994;83(4):885-98.doi.org/10.1182/blood. V83.4.885.885 Search in Google Scholar

7 Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of anti-platelet therapy for prevention of death, myocar-dial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71-86. doi: 10.1136/ bmj.324.7329.71. Search in Google Scholar

8 Bennett D, Yan B, Macgregor L, Eccleston D, Davis SM. A pilot study of resistance to aspirin in stroke patients. J Clin Neurosci. 2008;15(11):1204-9. doi: 10.1016/j. jocn.2008.01.006. Search in Google Scholar

9 Englyst NA, Horsfield G, Kwan J, Byrne CD. Aspirin resistance is more common in lacunar strokes than embolic strokes and is related to stroke severity. J Cereb Blood Flow Metab. 2008;28(6):1196-203. doi: 10.1038/jcbfm.2008.9. Search in Google Scholar

10 Berrouschot J, Schwetlick B, von Twickel G, Fischer C, Uhlemann H, Siegemund T, Siegemund A, Roessler A. Aspirin resistance in secondary stroke prevention. Acta Neurol Scand. 2006;113(1):31-5. doi: 10.1111/j.1600-0404.2005.00419.x. Search in Google Scholar

11 Helgason CM, Bolin KM, Hoff JA, et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke. 1994;25(12):2331-6. doi: 10.1161/01.str.25.12.2331. Search in Google Scholar

12 Macchi L, Petit E, Brizard A, Gil R, Neau JP. Aspirin resistance in vitro and hypertension in stroke patients. J Thromb Haemost. 2004;2(11):2051-3. doi: 10.1111/j.1538-7836.2004.00953.x. Search in Google Scholar

13 Grundmann K, Jaschonek K, Kleine B, Dichgans J, Topka H. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol. 2003;250(1):63-6. doi: 10.1007/s00415-003-0954-y. Search in Google Scholar

14 Patel S, Arya V, Saraf A, Bhargava M, Agrawal CS. Aspirin and Clopidogrel Resistance in Indian Patients with Ischemic Stroke and its Associations with Gene Polymorphisms: A Pilot Study. Ann Indian Acad Neurol. 2019;22(2):147-152. doi: 10.4103/aian.AIAN_4_18. Search in Google Scholar

15 Sanderson S, Emery J, Baglin T, Kinmonth AL. Narrative review: aspirin resistance and its clinical implications. Ann Intern Med. 2005;142(5):370-80. doi: 10.7326/0003-4819-142-5-200503010-00012. Search in Google Scholar

16 Patrono C. Aspirin resistance: Definition, mechanisms and clinical read-outs. J. Thromb. Haemost. 2003, 1, 1710–1713. doi: 10.1046/j.1538-7836.2003.00284.x. Search in Google Scholar

17 Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet 2006; 367, 606–617. DOI: https://doi.org/10.1016/S0140-6736(06)68040-9 Search in Google Scholar

18 Greer DM. Aspirin and antiplatelet agent resistance: implications for prevention of secondary stroke. CNS Drugs. 2010; 24(12):1027-40. doi: 10.2165/11539160-0000000000-00000. Search in Google Scholar

19 Aspirin resistance: is it real? Is it clinically significant? Am J Med. 2007;120(1):1-4. doi: 10.1016/j.amjmed.2006.08.023. Search in Google Scholar

20 Yi X, Zhou Q, Lin J, Chi L. Aspirin resistance in Chinese stroke patients increased the rate of recurrent stroke and other vascular events. Int J Stroke. 2013;8(7):535-9. doi: 10.1111/j.1747-4949.2012.00929.x. Search in Google Scholar

21 Roman-Gonzalez A, Naranjo CA, Cardona-Maya WD, et al. Frequency of Aspirin Resistance in Ischemic Stroke Patients and Healthy Controls from Colombia. Stroke Res Treat. 2021; 21;2021:9924710. doi: 10.1155/2021/9924710. Search in Google Scholar

22 Ikeda T, Taniguchi R, Watanabe S, et al. Characterization of the antiplatelet effect of aspirin at enrollment and after 2-year follow-up in a real clinical setting in Japan. Circ J. 2010;74(6):1227-35. doi: 10.1253/circj.cj-09-0927. Search in Google Scholar

23 Derle E, Öcal R, Kibaroğlu S, et al. Aspirin resistance in cerebrovascular disease and the role of glycoprotein IIIa polymorphism in Turkish stroke patients. Blood Coagul Fibrinolysis. 2016;27(2):169-75. doi: 10.1097/ MBC.0000000000000404. Search in Google Scholar

24 Khan H, Kanny O, Syed MH, Qadura M. Aspirin Resistance in Vascular Disease: A Review Highlighting the Critical Need for Improved Point-of-Care Testing and Personalized Therapy. Int J Mol Sci. 2022;23(19):11317. Doi: 10.3390/ ijms231911317. Search in Google Scholar

25 Chen WH, Lee PY, Ng W, et al. Relation of aspirin resistance to coronary flow reserve in patients undergoing elective percutaneous coronary intervention. Am J Cardiol. 2005; 96(6):760-3. doi: 10.1016/j.amjcard.2005.04.056. Search in Google Scholar

26 Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ. 2008 Jan 26;336(7637):195-8. doi: 10.1136/bmj.39430.529549.BE. Epub 2008 Jan 17. PMID: 18202034; PMCID: PMC2213873 Search in Google Scholar

27 Wiśniewski A, Sikora J, Filipska K, Kozera G. Assessment of the relationship between platelet reactivity, vascular risk factors and gender in cerebral ischaemia patients. Neurol Neurochir Pol. 2019;53(4):258-264. doi: 10.5603/PJNNS. a2019.0028. Search in Google Scholar

28 Sadeghi M, Emami A, Ziyaei N, Yaran M, Golabchi A, Sadeghi A. Aspirin resistance and ischemic heart disease on Iranian experience. Adv Biomed Res. 2012;1:33. doi: 10.4103/2277-9175.99345. Search in Google Scholar

29 Liu XF, Cao J, Fan L, et al. Prevalence of and risk factors for aspirin resistance in elderly patients with coronary artery disease. J Geriatr Cardiol. 2013;10(1):21-7. doi: 10.3969/j.issn.1671-5411.2013.01.005. Search in Google Scholar

30 Kahraman S, Dogan A, Ziyrek M, Usta E, Demiroz O, Ciftci C. The association between aspirin resistance and extent and severity of coronary atherosclerosis. North Clin Istanb. 2018;5(4):323-328. doi: 10.14744/nci.2017.26779. Search in Google Scholar

31 Fong J, Cheng-Ching E, Hussain MS, Katzan I, Gupta R. Predictors of biochemical aspirin and clopidogrel resistance in patients with ischemic stroke. J StrokeCerebrovasc Dis. 2011;20(3):227-30.doi:10.1016/j.jstrokecerebrovasdis.2009.12.004. Search in Google Scholar

32 Meade TW, Brennan PJ. Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ 2000;321:13–7. doi: 10.1136/bmj.321.7252.13. Search in Google Scholar

33 Gum PA, Kottke-Marchant K, Poggio Edet al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 2001;88(3):230-235. doi: 10.1016/s0002-9149(01)01631-9. Search in Google Scholar

34 Anıl B, Sultan Ç, Vildan Y, Murat Ç, Songül Ş. South. Clin. Ist. Euras2018;29(4):225-229. DOI: 10.14744/scie.2018.40427 Search in Google Scholar

35 Tasdemir E, Toptas T, Demir C, Esen R, Atmaca M. Aspirin resistance in patients with type II diabetes mellitus. Ups J Med Sci. 2014;119(1):25-31. doi: 10.3109/03009734.2013.861549. Search in Google Scholar

36 Vardhan G, Kumar V, Agrawal M, et al. Association between Aspirin Resistance and Blood Lipid Profile in Patients of Ischemic Stroke: A Meta-Analysis. Authorea Preprints; 2023. doi: 10.22541/au.167540249.98774953/v1. Search in Google Scholar

37 Di Chiara J, Bliden KP, Tantry US, et al. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes. 2007;56(12):3014-9. doi: 10.2337/db07-0707. Search in Google Scholar

38 Fateh-Moghadam S, Plöckinger U, Cabeza N, et al. Prevalence of aspirin resistance in patients with type 2 diabetes. Acta Diabetol. 2005;42(2):99-103. doi:10.1007/s00592-005-0186-y. Search in Google Scholar

39 Schwartz KA. Aspirin resistance: a clinical review focused on the most common cause, non-compliance. Neurohospitalist. 2011;1(2):94-103. doi: 10.1177/1941875210395776. Search in Google Scholar

40 Kasotakis G, Pipinos II, Lynch TG. Current evidence and clinical implications of aspirin resistance. J Vasc Surg. 2009;50(6):1500-10. doi: 10.1016/j.jvs.2009.06.023. Search in Google Scholar

41 Helgason CM, Bolin KM, Hoff JA, et al. Development of aspirin resistance in persons with previous ischemic stroke. 1994; Stroke, 25:2331-2336.DOI: 10.1161/01.str.25.12.2331. Search in Google Scholar

42 Andersen K, Hurlen M, Arnesen H, Seljeflot I. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res. 2002 Oct 1;108(1):37-42. doi: 10.1016/s0049-3848(02)00405-x. PMID: 12586130. Search in Google Scholar

43 K.H Grotemeyer. Effects of acetylsalicylic acid in stroke patients. Evidence of nonresponders in a subpopulation of treated patients. 1991; Thromb Res, 63:587-593. doi: 10.1016/0049-3848(91)90085-b. Search in Google Scholar

44 Al-Jabi SW. Global Trends in Aspirin Resistance-Related Research from 1990 to 2015: A Bibliometric Analysis. Basic Clin Pharmacol Toxicol. 2017;121(6):512-519. doi: 10.1111/ bcpt.12840. Search in Google Scholar